Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etoriga-T is an oral fixed-dose combination tablet containing the selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib and the centrally acting muscle relaxant thiocolchicoside. Developed and marketed by Auriga Laboratories, it is indicated for the treatment of acute pain, inflammation, and muscle spasms associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and low back pain. Etoricoxib provides anti-inflammatory and analgesic effects by inhibiting prostaglandin synthesis, while thiocolchicoside acts as a competitive GABAA receptor antagonist and glycine receptor agonist to reduce muscle stiffness and spasms without causing significant sedation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etoricoxib + thiocolchicoside.